0001179110-22-002324.txt : 20220318 0001179110-22-002324.hdr.sgml : 20220318 20220318163651 ACCESSION NUMBER: 0001179110-22-002324 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210715 FILED AS OF DATE: 20220318 DATE AS OF CHANGE: 20220318 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Tessari Eben CENTRAL INDEX KEY: 0001867899 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38492 FILM NUMBER: 22753027 MAIL ADDRESS: STREET 1: C/O KINIKSA PHARMACEUTICALS LTD. STREET 2: CLARENDON HOUSE, 2 CHURCH STREET CITY: HAMILTON STATE: D0 ZIP: HM11 FORMER NAME: FORMER CONFORMED NAME: Tessan Eben DATE OF NAME CHANGE: 20210616 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kiniksa Pharmaceuticals, Ltd. CENTRAL INDEX KEY: 0001730430 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: D0 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: CLARENDON HOUSE STREET 2: 2 CHURCH STREET CITY: HAMILTON STATE: D0 ZIP: HM11 BUSINESS PHONE: 7814399100 MAIL ADDRESS: STREET 1: CLARENDON HOUSE STREET 2: 2 CHURCH STREET CITY: HAMILTON STATE: D0 ZIP: HM11 4 1 edgar.xml FORM 4 - X0306 4 2021-07-15 0 0001730430 Kiniksa Pharmaceuticals, Ltd. KNSA 0001867899 Tessari Eben C/O KINIKSA PHARMACEUTICALS, LTD. CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11 BERMUDA 0 1 0 0 Chief Operating Officer Class A Common Share 2021-07-15 4 A 0 868 11.49 A 106810 D Class A Common Share 2022-01-15 4 A 0 970 9.63 A 107780 D Class A Common Share 2022-03-16 4 M 0 1964 A 109744 D Class A Common Share 2022-03-16 4 F 0 681 10.13 D 109063 D Restricted Share Unit 2022-03-16 4 M 0 1964 0 D Class A Common Share 1964 5892 D The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 1, 2021 to July 15, 2021. The acquisition of such shares was exempt pursuant to Rule 16b-3(c). The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of July 16, 2021 to January 15, 2022. The acquisition of such shares was exempt pursuant to Rule 16b-3(c). Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021. Madelyn Zeylikman, Attorney-in-Fact for Eben Tessari 2022-03-18